OVERVIEW
Lidocaine 5% patch is indicated for the relief of pain associated with postherpetic neuralgia (PHN). Lidocaine is an amide-type local anesthetic agent whose neuronal membrane stabilizing effect produces a local analgesic effect when applied transdermally. The lidocaine penetration into intact skin is adequate to produce an analgesic effect, but less than the amount needed to produce a complete sensory block.

RECOMMENDED AUTHORIZATION CRITERIA
Coverage of lidocaine 5% patch is recommended in those who meet the following criteria:

Food and Drug Administration (FDA)-Approved Indications


Other Uses with Supportive Evidence

1. Low Back Pain. Approve after trying at least three prescription pharmacologic therapies with each one from a different class of medication used to treat low back pain (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] {e.g., etodolac, meloxicam, nambutone}, [muscle relaxants] (e.g., carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine), opioids, celecoxib, tramadol, gabapentin, tricyclic antidepressants [TCAs] (e.g., amitriptyline, desipramine, imipramine, nortriptyline).


3. Osteoarthritis (OA). Approve after trying at least three prescription pharmacologic therapies with each one from a different class of medication used for the treatment of OA of the hand, hip, and knee (e.g., celecoxib, nonsteroidal anti-inflammatory drugs [NSAIDs] {e.g., etodolac, meloxicam, nambutone}, salicylates, tramadol, opioids, intraarticular glucocorticoids, intraarticular hyaluronan, topical capsaicin, and topical methylsalicylate).

Approval Duration: 365 days (1 year)
References

